JHL Biotech to Provide Manufacturing Services to BeiGene for Immuno-oncology Program13 Jun 2016
WUHAN, China, June 13, 2016—JHL Biotech, Inc. (TWSE: 6540) (“JHL”) announces that it has entered into a contract manufacturing agreement with BeiGene, Ltd. (NASDAQ: BGNE) (“BeiGene”) for development and IND-enabling production of a new biologic in BeiGene’s immuno-oncology pipeline. This marks the third collaboration between the two companies, with JHL providing services to BeiGene for the development and manufacturing of certain early stage pipeline programs.
JHL Biotech Opens Innovative Biosimilars Manufacturing Facility in China10 May 2016
GE Healthcare delivers world’s first modular manufacturing solution based on single- use bioprocessing technology in just 18 months